Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives

doi:10.4330/wjc.v16.i5.240

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2059)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

HTML

1501

Figures (1-2)

Tables (1-3)

Sum=1699

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=70

May 26, 2024 (publication date) through Aug 24, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Cardiol. May 26, 2024; 16(5): 240-259
Published online May 26, 2024. doi: 10.4330/wjc.v16.i5.240

Open in New Tab Full Size Figure Download Figure

Figure 1 Cardiovascular benefits of sodium glucose cotransporter 2 inhibitors - the evidence from trials. CV: Cardiovascular; HHF: Hospitalisation due to heart failure; 3P-MACE: 3 point - major adverse cardiovascular event; HFrEF: Heart failure with reduced ejection fraction; HFpEF: Heart failure with preserved ejection fraction; HFmrEF: Heart failure with mildly reduced ejection fraction; AHF: Acute heart failure; OSA: Obstructive sleep apnea; NAFLD: Non-alcoholic fatty liver disease; eGFR: Estimated glomerular filtration rate; BP: Blood pressure.

Open in New Tab Full Size Figure Download Figure

Figure 2 Mechanisms of cardiovascular benefits of sodium glucose cotransporter 2 inhibitors. CV: Cardiovascular; SGLT2i: Sodium glucose cotransporter-2 inhibitors.

Citation: Mondal S, Pramanik S, Khare VR, Fernandez CJ, Pappachan JM. Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives. World J Cardiol 2024; 16(5): 240-259
URL: https://www.wjgnet.com/1949-8462/full/v16/i5/240.htm
DOI: https://dx.doi.org/10.4330/wjc.v16.i5.240